NASDAQ: SUPN
Supernus Pharmaceuticals Inc Stock

$31.52+0.36 (+1.16%)
Updated Jun 30, 2025
SUPN Price
$31.52
Fair Value Price
N/A
Market Cap
$1.76B
52 Week Low
$25.55
52 Week High
$40.28
P/E
27.89x
P/B
1.71x
P/S
2.74x
PEG
0.93x
Dividend Yield
N/A
Revenue
$668.00M
Earnings
$61.91M
Gross Margin
88.4%
Operating Margin
13.74%
Profit Margin
9.3%
Debt to Equity
0.31
Operating Cash Flow
$164M
Beta
0.69
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

SUPN Overview

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine SUPN's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Pharmaceutical

Industry Rating
B
SUPN
Ranked
#20 of 60

Top Ranked Stocks in Industry

View Top Pharmaceutical Stocks

Be the first to know about important SUPN news, forecast changes, insider trades & much more!

SUPN News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SUPN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SUPN ($31.52) is trading above its intrinsic value of $18.46, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SUPN is good value based on its earnings relative to its share price (27.89x), compared to the US market average (32.47x)
P/E vs Market Valuation
SUPN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more SUPN due diligence checks available for Premium users.

Valuation

SUPN fair value

Fair Value of SUPN stock based on Discounted Cash Flow (DCF)

Price
$31.52
Fair Value
$93.63
Undervalued by
66.33%
SUPN ($31.52) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SUPN price to earnings (PE)

For valuing profitable companies with steady earnings

Company
27.89x
Industry
-31.27x
Market
32.47x
SUPN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SUPN is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

SUPN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.71x
Industry
2.23x
SUPN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SUPN price to earnings growth (PEG)

For valuing profitable companies with growth potential

SUPN is good value based... subscribe to Premium to read more.
PEG Value Valuation

SUPN's financial health

Profit margin

Revenue
$149.8M
Net Income
-$11.8M
Profit Margin
-7.9%
SUPN's Earnings (EBIT) of $91.80M... subscribe to Premium to read more.
Interest Coverage Financials
SUPN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.3B
Liabilities
$316.6M
Debt to equity
0.31
SUPN's short-term assets ($687.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SUPN's short-term assets ($687.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SUPN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SUPN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$30.6M
Investing
$37.3M
Financing
-$21.4M
SUPN's operating cash flow ($164.15M)... subscribe to Premium to read more.
Debt Coverage Financials

SUPN vs Pharmaceutical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
SUPNC$1.76B+1.16%27.89x1.71x
INDVA$1.84B+5.66%245.67x-6.45x
EVOC$1.49B+0.96%N/A1.44x
ANIPB$1.41B-0.38%-51.79x3.38x
DVAXC$1.19B+0.10%-20.24x2.24x

Supernus Pharmaceuticals Stock FAQ

What is Supernus Pharmaceuticals's quote symbol?

(NASDAQ: SUPN) Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol SUPN. Supernus Pharmaceuticals stock quotes can also be displayed as NASDAQ: SUPN.

If you're new to stock investing, here's how to buy Supernus Pharmaceuticals stock.

What is the 52 week high and low for Supernus Pharmaceuticals (NASDAQ: SUPN)?

(NASDAQ: SUPN) Supernus Pharmaceuticals's 52-week high was $40.28, and its 52-week low was $25.55. It is currently -21.75% from its 52-week high and 23.37% from its 52-week low.

How much is Supernus Pharmaceuticals stock worth today?

(NASDAQ: SUPN) Supernus Pharmaceuticals currently has 55,989,623 outstanding shares. With Supernus Pharmaceuticals stock trading at $31.52 per share, the total value of Supernus Pharmaceuticals stock (market capitalization) is $1.76B.

Supernus Pharmaceuticals stock was originally listed at a price of $5.37 in May 1, 2012. If you had invested in Supernus Pharmaceuticals stock at $5.37, your return over the last 13 years would have been 486.96%, for an annualized return of 14.58% (not including any dividends or dividend reinvestments).

How much is Supernus Pharmaceuticals's stock price per share?

(NASDAQ: SUPN) Supernus Pharmaceuticals stock price per share is $31.52 today (as of Jun 30, 2025).

What is Supernus Pharmaceuticals's Market Cap?

(NASDAQ: SUPN) Supernus Pharmaceuticals's market cap is $1.76B, as of Jul 2, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Supernus Pharmaceuticals's market cap is calculated by multiplying SUPN's current stock price of $31.52 by SUPN's total outstanding shares of 55,989,623.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.